Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 44 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Smart Pharma from Elsene, company number BE0588980436, closed financial year 2025 with a result of € -37,265 after tax. For that financial year Smart Pharma recorded a gross margin of € 55,858 and equity of € 84,109. Compared with financial year 2024, the result moved from € -38,424 to € -37,265. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.
€ 84,109
▼ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -37,265
▲ 3 % less loss than in 2024
Profit after tax over the fiscal year.
€ 15,179
▲ 54% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 77,909.
People and assets in 2025
1.1
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 73,872
▲ 7% vs 2024
€ 67,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 186,344
▼ 12% vs 2024
€ 24,991 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 96,409
▲ 26% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,732
▲ 48% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 97,170 | € 103,730 | € 64,649 | € 55,858 | ▼ 14% |
| Profit after taxes | € -1,055 | € -536 | € -38,424 | € -37,265 | ▲ € 1,159 |
| Equity | € 160,335 | € 159,798 | € 121,374 | € 84,109 | ▼ 31% |
| Total debts | € 389,246 | € 344,138 | € 369,228 | € 399,368 | ▲ 8% |
| Cash | € 28,207 | € 16,948 | € 9,880 | € 15,179 | ▲ 54% |
| Land & buildings | € 287,632 | € 283,714 | € 274,462 | € 265,210 | ▼ 3% |
| Retained profit | € 154,135 | € 153,598 | € 115,174 | € 77,909 | ▼ 32% |
| Bank debt | € 292,421 | € 252,734 | € 212,245 | € 186,344 | ▼ 12% |
| Balance sheet total | € 549,581 | € 503,937 | € 490,603 | € 483,477 | ▼ 1% |
| Employees (FTE) | 1 | 1 | 1 | 1.1 | ▲ 0.1 |
By gross margin, Smart Pharma ranks 31st of 38 companies with main activity “Detailhandel in farmaceutische producten” in Elsene that publish figures (fiscal year 2025).
Key figures of Smart Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Smart Pharma the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Smart Pharma?
What happened at Smart Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 37,265. filed late Source: NBB ↗
- ROZENTAL & HERMAN SRL became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Elsene. KBO
In short
From € 1,055 loss in 2022 to € 37,265 loss in 2025.
On average € 50,800 of value added per employee in 2025.
Management
The stake of ROZENTAL & HERMAN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Smart PharmaBehind Smart Pharma is ROZENTAL & HERMAN SRL. The shares are held by ROZENTAL & HERMAN (100%).
Directors
According to the 2025 annual accounts
Director · represented by Philippe HERMAN
since 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Waterloose Steenweg 606A
1050 Elsene
Waterloose Steenweg 606 box A
1050 Elsene
Active since 29 January 2015
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Elsene
Same main activity (Detailhandel in farmaceutische producten), 39 active companies in Elsene, largest first.
€ 825,140 gross margin · 2025
€ 793,112 gross margin · 2025
€ 559,341 gross margin · 2025
€ 528,662 gross margin · 2025
€ 485,409 gross margin · 2025
€ 414,458 gross margin · 2025
Website
Technologies
Hosting & Email
Email provider
OVH Mail
Hosting
OVH, FR
DNS
OVH DNS
Website info
Features
Security
Network
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- APPELBOOM Maxime Pierre Marcel(oprichter) 50%
- MENDOZA Laurent Pierre Louis(oprichter) 50%
Details
- Company number
- 0588.980.436
- VAT number
- BE 0588.980.436
- Registered office
- Waterloose Steenweg 606A, 1050 Elsene
- Names & denominations
- Smart Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 January 2015
- Peppol
- Active · Active since 26 Nov 2025
- Contact
- smartpharma.brussels
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Groothandel in farmaceutische en medische artikelen
Overige vormen van onderwijs
Overige financiële dienstverlening, neg
Ontwikkeling van residentiële bouwprojecten
+6